‘Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection’ by Eugene P. Duff et al. was published in Nature Medicine at 10:00 UK time on Thursday 30th January.

Merck and Seagen are already working together ... including an ongoing arbitration process between Seagen and Eisai over technology used in the latter's AstraZeneca-partnered HER2 drug Enhertu ...